Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson's disease induced by the Japanese encephalitis virus

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 87-95

  Minami, M ^a,d   Hamaue, N ^a   Hirafuji, M ^a   Saito, H ^a   Hiroshige, T ^a   Ogata, A ^b   Tashiro, K ^b   Parvez, S H ^c  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CNRS   (France)

^d Touei Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; DEXAMETHASONE; DIAZEPAM; DIETHYLDITHIOCARBAMIC ACID; ISATIN; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

BEHAVIOR; BRADYKINESIA; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; HUMAN; JAPANESE ENCEPHALITIS VIRUS; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RODENT; ANIMAL; ARTICLE; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; NEWBORN; PATHOGENICITY; PHYSIOLOGY; RAT; VIROLOGY;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ISATIN; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; PARKINSON DISEASE; RATS; TYROSINE 3-MONOOXYGENASE;

EID: 34248547560     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_10     Document Type: Review

References (97)

1. Adams JD, Odunze IN (1991) Oxygen free radicals and Parkinson's disease. Free Radical Biol Med 10: 161-169
2. Alves RSC, Barbosa ER, Scaff M (1992) Postvaccinial parkinsonism. Movement Disorders 7: 178-180
3. Appel SH, Le WD, Tajti J, Haverkamp LJ, Engelhardt JI (1992) Nigral damage and dopaminergic hypofunction in mesencephalon-immunized guinea pigs. Ann Neurol 32: 494-501
4. Armando I, Barontini M, Levin G, Simsolo R, Glover V, Sandler M (1984) Exercise increases endogenous urinary monoamine oxidase benzodiazepine receptor ligand inhibitory activity in normal children. J Auton Nerv Syst 11: 95-100
5. Armando I, Levin G, Barontini M (1988) Stress increases endogenous benzodiazepine receptor ligand-monoamine oxidase inhibitory activity (tribulin) in rat tissues. J Neural Transm 71: 29-37
6. Battacharya SK, Glover V, Sandler M, Clow A, Topham A, Bernadt M, Murray R (1982) Raised endogenous monoamine oxidase inhibitor output in postwithdrawal alcoholics: effects of L-dopa and ethanol. Biol Psychiat 17: 829-836
7. Battacharya SK, Acharya SB (1993) Further investigations on the anxiogenic effects of isatin. Biog Amines 9: 453-463
8. Battacharya SK, Chakrabarti A, Sandler M, Glover V (1996) Anxyolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsycho-pharmacol 15: 199-206
9. Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35: 949-956
10. Bansal RC, Kaur P, Kiran R (1988) Mode of interaction of isatin with rat liver alkaline phosphatase. Res Bull (Science) PU Chandigarh 39: 71-76
11. Berry MD, Juorio AV, Paterson IA (1994) Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 44: 141-161
12. Blaschko H (1973) Amine oxidase. In: Boyer PD, Lardy H, Myrback K (eds) The Enzymes. 3rd ed, vol 8, Academic Press, New York, pp 337-351
13. Bojinov S (1971) Encephalitis with acute parkinsonian syndrome and bilateral inflammatory necrosis of the substantia nigra. J Neurol Sci 12: 383-415
14. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546-4550
15. Bursey M, Eichenbaum H (1996) Conservation of hippocampal memory function in rats and humans. Nature 379: 255-257
16. Calne DB, Langston JW (1983) Aetiology of Parkinson's disease. Lancet 2: 1457-1459
17. Chocholova L, Kolinova M (1979) Effect of isatin on audiogenic seizures in rats and its relationship to electrographic and behavioral phenomena. Physiol Bohemoslov 28: 495-502
18. Chocholova L, Kolinova M (1981) Effect of isatin (2, 3 dioxyindoline) on physiological and pathological electrographic manifestations of vigilance. Physiol Bohemoslov 30: 129-137
19. Clow A, Glover V, Armando I, Sandler M (1983) New endogenous benzodiazepine receptor ligand in human urine: identity with endogenous MAO inhibitor? Life Sci 33: 735-741
20. Clow A, Glover V, Weg MW, Walker PL, Sheehan DV, Carr DB, Sandler M (1988a) Urinary catecholamine metabolite and tribulin output during lactate infusion. Br J Psychiatry 152: 122-126
21. Clow A, Glover V, Sandler M, Tiller J (1988b) Increased urinary tribulin output in generalized anxiety disorder. Psychopharmacol 95: 378-380
22. Cohen G (1986) Monoamine oxidase, hydrogen peroxidase and Parkinson's disease. Adv Neurol 45: 119-125
23. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836
24. Dickerson RB, Newton JR, Hansen JE (1952) Diagnosis and immediate prognosis of Japanese B encephalitis. Am J Med 12: 277-288
25. Duvoisin RC, Yahr MD (1965) Encephalitis and parkinsonism. Arch Neurol 12: 227-239
26. Elsworth JD, Dewar D, Glover V, Goodwin BL, Clow A, Sandler M (1986) Purification and characterization of tribulin, an endogenous inhibitor of monoamine oxidase and benzodiazepine receptor binding. J Neural Transm 67: 45-56
27. Fishman PS, Gass JS, Swoveland PT, Lavi E, Highkin MK, Weiss SR (1985) Infection of the basal ganglia by a murine coronavirus. Science 229: 877-879
28. Geddes JF, Hughes AJ, Lees AJ, Daniel SE (1993) Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. Brain 116: 281-302
29. Gerlach M, Youdim MB, Riederer P (1996) Pharmacology of selegiline. Neurology 47 [Suppl 3]: S137-S145
30. Gibb WRG, Lees AJ (1987) The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. Acta Neuropathol (Berl) 73: 195-201
31. Glover V, Reveley MA, Sandler M (1980) A monoamine oxidase inhibitor in human urine. Biochem Pharmacol 29: 467-470
32. Glover V, Halket JM, Watkins PJ, Clow A, Goodwin BL, Sandler M (1988) Isatin: identity with the purified endogenous monoamine oxidase inhibitor tribulin. J Neurochem 51: 656-659
33. Glover V, Bhattacharya SK, Sandler M (1991) Isatin-a new biological factor. Indian J Exp Biol 29: 1-5
34. Glover V, Clow A, Sandler M (1993) Effects of dopaminergic drugs on superoxide dismutase: implications for senescence. J Neurol Transm 40 [Suppl]: 37-45
35. Glover V, Medvedev A, Sandler M (1995) Isatin is a potent endogenous antagonist of guanylate cyclase-coupled atrial natriuretic peptide receptors. Life Sci 57: 2073-2079
36. Gorell JM, Czarnecki B (1986) Pharmacological evidence for direct dopaminergic regulation of striatal acetylcholine release. Life Sci 38: 2239-2246
37. Goto A (1962) Follow-up study of Japanese B encephalitis. Psychiat Neurol Jpn (Tokyo) 64: 236-266
38. Hamaue N, Minami M, Kanamaru Y, Togashi M, Monma Y, Ishikura M, Mahara R, Yamazaki N, Togashi H, Saito H, Parvez SH (1992) Endogenous monoamine oxidase (MAO) inhibitor (tribulin-like activity) in the brain and urine of stroke-prone SHR. Biog Amines 8: 401-412
39. Hamaue N, Minami M, Kanamaru Y, Ishikura M, Yamazaki N, Saito H, Parvez SH (1994) Identification of isatin, an endogenous MAO inhibitor, in the brain of stroke-prone SHR. Biog Amines 10: 99-110
40. Hamaue N, Yamazaki N, Minami M, Endo T, Hirafuji M, Monma Y, Togashi H (1998) Determination of isatin, an endogenous monoamine oxidase inhibitor, in urine and tissues of rats by HPLC. Gen Pharmacol 30: 387-391
41. Hamaue N, Yamazaki N, Minami M, Endo T, Hirafuji M, Monma Y, Togashi H, Saito H, Parvez SH (1999a) Effects of isatin, an endogenous MAO inhibitor, on acetylcholine and dopamine levels in the rat striatum. Biog Amines 15: 367-377
42. Hamaue N, Minami M, Hirafuji M, Terado M, Machida M, Yamazaki N, Yoshioka M, Ogata A, Tashiro K (1999b) Isatin, an endogenous MAO inhibitor, as a new biological modulator. CNS Drug Rev 5: 331-346
43. Hamaue N, Yamazaki N, Terado M, Minami M, Ohno K, Ide H, Ogata A, Honma S, Tashiro K (2000) Urinary isatin concentrations in patients with Parkinson's disease determined by a newly developed HPLC-UV method. Res Commun Mol Pathol Pharmacol 108: 63-73
44. Hamaue N, Minami M, Terado M, Hirafuji M, Endo T, Machida M, Hiroshige T, Ogata A, Tashiro K, Saito H, Parvez SH (2004) Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus. NeuroToxicology 25: 205-213
45. Hoehn MM, Yarh MD (1967) Parkinsonism: onset, progression and mortality. Neurolol 17: 427-442
46. Hota D, Acharya SB (1994) Studies on peripheral actions of isatin. Ind J Exp Biol 32: 710-717
47. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580
48. Hudson AJ, Rice GPA (1990) Similarities of Guamanian ALS/PD to postencephalitic parkinsonism/ALS: possible viral cause. Can J Neurol Sci 17: 427-433
49. 1 receptors. J Pharmacol Exp Ther 266: 557-562
50. Jarman J, Przylorowska A, Glover V, Halket J, Davies PT, Rose FC, Sandler M (1991) Urinary output of endogenous monoamine oxidase inhibitor and isatin during acute migraine attack. J Neural Transm Gen Sect 84: 129-134
51. Johnson RT, Burke DS, Elwell M, Leake CJ, Nisalak A, Hoke CH, Lorsomrudee W (1985) Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol 18: 567-573
52. Knoll J (1978) The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm 43: 177-198
53. Kristensson K (1992) Potential role of viruses in neuro-degeneration. Mol Chem Neuropathol 16: 45-58
54. Kumar P, Dani HM, Trehan S (1977) Effect of isatin testicular hyaluronidase. Ind J Exp Biol 15: 655-656
55. Kumar P, Bansal RC, Mahmood A (1993) Isatin, an inhibitor of acetyl-cholinesterase activity in rat brain. Biog Amines 9: 281-289
56. Lehmann J, Langer SZ (1983) The striatal cholinergic interneuron: Synaptic target of dopaminergic terminals? Neurosci 10: 1105-1120
57. Matsumoto M, Togashi H, Yoshioka M, Hirokami M, Morii K, Saito H (1990) Simultaneous high-performance liquid chromatographic determination of norepinephrine, serotonin, acetylcholine and their metabolites in the cerebrospinal fluid of anaesthetized normotensive rats. J Chromatogr 526: 1-10
58. McIntyre IM, Norman TR (1990) Serotonergic effects of isatin: an endogenous MAO inhibitor related to tribulin. J Neural Transm 79: 35-40
59. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24: 574-576
60. Medvedev AE, Clow A, Sandler M, Glover V (1996) Isatin: A link between natriuretic peptides and monoamines? Biochem Pharmacol 52: 385-391
61. Minami M, Senjo M, Togashi H, Yoshioka M, Saito H, Kawaguchi H, Takebayashi K, Parvez H (1988) Kidney glutathione S-transferase activity and kidney monoamine oxidase activity in stroke cases of SHRSP. Biog Amines 5: 517-526
62. Morita K, Tanaka M, Igarashi A (1991) Rapid identification of dengue virus serotypes by using polymerase chain reaction. J Clin Microbiol 29: 2107-2110
63. Muller M, Schramek J (1989) Combined application of propranolol and local anesthetics: enhanced anticonvulsant action. Biomed Biochim Acta 4: 333-336
64. Nagatsu T, Yoshida M (1988) An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primate with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 87: 178-182
65. Nilsson OG, Leanza G, Bjkölund A (1992) Acetylcholine release in the hippocampus: regulation by monoaminergic afferents as assessed by in vivo microdialysis. Brain Res 584: 132-140
66. Ogata A, Nagashima K, Hall WW, Ichikawa M, Kimura-Kuroda J, Yasui K (1991) Japanese encephalitis virus neurotropism is dependent on the degree of neuronal maturity. J Virol 65: 880-886.
67. Ogata A, Tashiro K, Nukuzuma S, Nagashima K, Hall WW (1997) A rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurol Virol 3: 141-147
68. Ogata A, Nagashima K, Yasui K, Matsuura T, Tashiro K (1998) Sustained release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats. J Neurol Sci 159: 135-139
69. Ogata A, Hamaue N, Terado M, Minami M, Nagashima K, Tashiro K (2003) Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus. J Neurol Sci 206: 79-83
70. Ogata A, Hamaue N, Minami M, Yabe I, Kikuchi S, Sasaki H, Tashiro K (2004) Post-encephalitis parkinsonism: clinical features and experimental model. Biog Amines 18: 339-347
71. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmaco 50: 435-441
72. Ohue T, Koshimura K, Akiyama Y, Ito A, Kido T, Takagi Y, Miwa S (1992) Regulation of acetylcholine release in vivo from rat hippocampus by monoamines as revealed by novel column-switching HPLC with electrochemical detection. Brain Res 572: 340-344
73. Oxenkrug G, McIntyre I (1985) Stress-induced synthesis of melatonin; possible involvement of the endogenous monoamine oxidase inhibitor (tribulin). Life Sci 37: 1743-1746
74. Parvez H, Parvez S (1973) The effects of metopirone and adrenectomy on the regulation of the enzymes monoamine oxidase and catechol-O-methyl transferase in different brain regions. J Neurochem 20: 1011-1020
75. Paxinos G, Wason C (1980) The rat brain in stereotaxic coordinates. 2nd ed, New York, Academic Press Inc
76. Peturson H, Bhattacharya SK, Glover V, Sandler M, Lader MH (1982) Urinary monoamine oxidase inhibitor and benzodiazepine withdrawal. Br J Psychiat 140: 7-10
77. Riederer P, Sotic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals ferritin, glutathione and ascorbic acid in Parkinsonian brain. J Neurochem 52: 515-520
78. Sandler M (1982) The emergence of tribulin. Trends Pharmacol Sci 3: 471-472
79. 1 dopamine receptors in dopaminergic control of striatal cholinergic transmission. Life Sci 31: 2883-2890
80. Sethy VH, van Woert MH (1974) Regulation of striatal acetylcholine concentration by dopamine receptors. Nature 251: 529-530
81. Shoji H, Watanabe M, Itoh S, Kuwahara H, Hattori F (1993) Japanese encephalitis and parkinsonism. J Neurol 240: 59-60
82. Singh B, Sharma R, Sareen K, Sareen KN, Sohal MS (1977) Isatin enzyme interaction V. Activation of rat liver acid phosphatase. Enzyme 22: 256-261
83. Stadler H, Lloyd KG, Gadea-Ciria M, Bartholini G (1973) Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine. Brain Res 55: 476-480
84. Stoof JC, Drukarch B, DeBoer P, Westerink BHC, Groenewegen HJ (1992) Regulation of the activity of striatal cholinergic neurons by L-DOPA. Neurosci 47: 755-770
85. Sumiyoshi H, Mori C, Fuke I, Morita K, Kuhara S, Kondou J, Kikuchi Y, Nagamatu H, Igarashi A (1987) Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 161: 497-510
86. Susheela I, Singh B, Dani HM, Amma MKP, Sareen K (1969) Enzyme inhibition by isatin I. Inhibition of rat liver xanthine oxidase. Enzymol 37: 325-334
87. Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H (1995) The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med 181: 2161-2169
88. Tipton KF, Housy MD, Mantle TJ (1976) The nature and locations of the multiple forms of monoamine oxidase. In: Mary LC (ed) Monoamine oxidase: its inhibition. Elsevier, New York, pp 5-31
89. Tozawa Y, Ueki A, Manabe S, Matsushima K (1998) Stress-induced increase in urinary isatin excretion in rats: reversal by both dexamethasone and α-methyl-p-tyrosine. Biochem Pharmacol 56: 1041-1046
90. Ueki A, Willoughby J, Glover V, Sandler M, Stibbe K, Stern GM (1989) Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders. J Neural Transm 1: 263-268
91. Von Economo C (1917) Encephalitis lethargica. Wien klin Wschr 30: 581-585
92. Walters JH (1960) Post-encephalitic parkinson syndrome after meningoencephalitis due to coxsackie virus group B, type 2. New Eng J Med 263: 744-747
93. 2-receptor. Naunym-Schmied Arch Pharmacol 338: 250-255
94. Yahr MD (1978) Encephalitis lethargica (Von Economo's disease, epidemic encephalitis). In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology vol 34 Elsevier, Amsterdam, pp 451-457
95. Yang HYT, Neff NH (1974) The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189: 733-740
96. Yoshida M, Miwa T, Nagatsu T (1990) Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahy droisoquinoline: the behavioral and biochemical changes. Neurosci Lett 119: 109-113
97. Yumiler A (1990) The effect of isatin (tribulin) on metabolism of indoles in the rat brain and pineal: in vitro and pineal: in vitro and in vivo studies. Neurochem Res 15: 95-100